Directive 2004/18/EC
Section I: Contracting authority
I.1)Name, addresses and contact point(s)UK Shared Business Services Ltd
North Star House, North Star Avenue
Contact point(s): Procurement, Research Tenders
SN2 1FF Swindon
UNITED KINGDOM
E-mail:
Internet address(es):
General address of the contracting authority: www.uksbs.co.uk
Further information can be obtained from: The above mentioned contact point(s)
I.2)Type of the contracting authorityBody governed by public law
I.3)Main activityOther: Research
I.4)Contract award on behalf of other contracting authoritiesThe contracting authority is purchasing on behalf of other contracting authorities: yes
UK Shared Business Services Ltd
North Star House, North Star Avenue
SN2 1FF Swindon
UNITED KINGDOM
Section II.B: Object of the contract (Supplies or services)
II.1)Title attributed to the contract by the contracting authority:Supply of Proprietary Antibodies - Primary and Secondary, Polyclonal and Monoclonal
II.2)Type of contract and place of delivery or of performanceSupplies
Various UK locations.
NUTS code UK
II.3)Information on framework agreement
II.4)Short description of nature and quantity or value of supplies or services:There is a requirement for the provision of an extensive range of high quality off the shelf Antibodies; primary and secondary, monoclonal and polyclonal, including, but not limited to, modified, labelled antibodies and fragments for use in laboratories undertaking research in the UK Public Sector. This broad and diverse requirement extends from contracted Government and academic research laboratories involved with the life sciences, biological, medical and environmental research, through to chemical and physical research.
Estimated cost excluding VAT:
Range: between 2 000 000 and 10 000 000 GBP
Lots
This contract is divided into lots: no
II.5)Common procurement vocabulary (CPV) II.6)Scheduled date for start of award procedures
II.7)Information about Government Procurement Agreement (GPA)The contract is covered by the Government Procurement Agreement (GPA): yes
II.8)Additional information:UK Shared Business Services Ltd as the Contracting Authority is putting into place a Framework Agreement for Proprietary Antibodies for use by or on behalf of UK bodies.
These bodies include but are not limited to The Science and Technology Facilities Council, The Medical Research Council, The Engineering and Physical Sciences Research Council, The Economic and Social Research Council, The Natural Environment Research Council, The Arts and Humanities Research Council, The Biotechnology and Biological Sciences Research Council, The UK Shared Business Services Ltd, Central Government Departments and their Agencies, Non Departmental Public Bodies, NHS bodies, Local Authorities, Voluntary Sector Charities, and/or other private organisations acting as managing agents or procuring on behalf of these UK bodies. (see section VI.2, Additional Information).
Section III: Legal, economic, financial and technical information
III.1)Conditions relating to the contract
III.1.1)Main financing conditions and payment arrangements and/or reference to the relevant provisions governing them:
III.2)Conditions for participation
III.2.1)Information about reserved contracts
Section VI: Complementary information
VI.1)Information about European Union fundsThe contract is related to a project and/or programme financed by European Union funds: no
VI.2)Additional information:UK Shared Business Services Ltd as the Contracting Authority is putting into place a Framework Agreement for Proprietary Antibodies for use by the following bodies summarised in II.7 above (and any future successors to these organisations).
Detailed on the UK Shared Business Services Ltd website is a list of all organisations, institutes, centres and bodies (Authorised Entities) that may use any appropriately advertised Contract let by the UK Shared Business Services Ltd. The full list can be accessed from the following link :
http://www.ssc.rcuk.ac.uk/services/procure/contracts/Pages/default.aspx
VI.3)Information on general regulatory framework
VI.4)Date of dispatch of this notice:4.11.2013